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Abstract
Duchenne and Becker muscular dystrophy are X-linked neuromuscular disorders characterized by 
progressive muscle degeneration. Despite the involvement of multiple systems, secondary 
conditions among affected males have not been comprehensively described. Two hundred and nine 
caregivers of affected males (aged 3–31 years) identified by the Muscular Dystrophy Surveillance, 
Tracking, and Research Network completed a mailed survey that included questions about 
secondary conditions impacting multiple body functions. The five most commonly reported 
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conditions in males with Duchenne were cognitive deficits (38.4%), constipation (31.7%), anxiety 
(29.3%), depression (27.4%), and obesity (19.5%). Higher frequencies of anxiety, depression, and 
kidney stones, were found among non-ambulatory males compared to ambulatory males. Attention 
deficit hyperactivity disorder was more common in ambulatory than non-ambulatory males. These 
data support clinical care recommendations for monitoring of patients with Duchenne or Becker 
muscular dystrophy by a multidisciplinary team to prevent and treat conditions that may be 
secondary to the diagnosis.
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Introduction
Duchenne and Becker muscular dystrophies are the most common pediatric inherited 
muscular dystrophies1, 2. The most prominent feature is progressive muscle degeneration 
that leads to loss of ambulation, as well as primary multisystem complications involving the 
heart, skeletal and respiratory systems3. Multidisciplinary care is recommended for clinical 
management of Duchenne and Becker muscular dystrophies, and such care typically 
includes monitoring and treatment of complications, including oral corticosteroids to 
maintain muscle strength3–5.
Though focus on primary complications is important for diagnosis and clinical management 
of Duchenne and Becker muscular dystrophies, secondary complications may also develop 
and amplify the severity of disease4, 5. These complications, commonly referred to as 
secondary conditions, include additional physical or mental problems that are related to the 
underlying disease6. Previous studies have typically focused on a single or few conditions 
that could be considered secondary to a diagnosis of Duchenne muscular dystrophy7–25. 
Collectively, these studies suggest a higher than expected occurrence of conditions affecting 
cognition, behavior, gastrointestinal, and genitourinary functioning.
In this study, we surveyed caregivers of males with Duchenne or Becker muscular 
dystrophies identified through the population-based Muscular Dystrophy Surveillance, 
Tracking, and Research Network (MD STARnet) about the presence of secondary conditions 
affecting multiple body systems. The objectives of this study are to report the frequencies of 
a broader range of secondary conditions than previously reported by phenotype of Duchenne 
or Becker muscular dystrophy, and to evaluate whether frequencies of these conditions differ 
by ambulation status.
Methods
MD STARnet is a population-based surveillance system established in 2002 by the Centers 
for Disease Control and Prevention to determine the prevalence of Duchenne and Becker 
muscular dystrophies and track clinical practices and health outcomes26. Beginning in 2004, 
MD STARnet retrospectively identified and longitudinally followed individuals who were 
born since January 1, 1982, diagnosed by December 31, 2011, and resided in four US sites: 
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Arizona, Colorado, Iowa, and western New York State. In 2005 and 2008, Georgia and 
Hawaii, respectively, joined the network. MD STARnet used medical record data and 
pertinent state (e.g. state vital records, hospital discharge and emergency room visits) and 
national data (e.g. national death index) to describe the care and outcomes of these 
individuals. Annual follow-up abstraction was attempted for at least one year for ascertained 
individuals. Individuals identified before September 2011 were followed through December 
2011, and those identified between September 2011 and December 2011 were followed 
through December 2012. A committee of clinical experts reviewed clinical and laboratory 
data to assign each individual a case definition designation (definite, probable, possible, 
asymptomatic, affected female, or not Duchenne or Becker muscular dystrophy). The data 
used for assigning the case definition included clinical symptoms, age at onset of symptoms, 
diagnostic testing (i.e. creatine kinase value, DMD mutation analysis, muscle biopsy results, 
and family history24. Full descriptions of MD STARnet surveillance methods and case 
definitions have been published previously26, 27.
Survey Collection
The Family Quality of Life Survey was developed by MD STARnet investigators and 
inquired about issues such as family quality of life, social support and stress, spirituality, and 
the affected male’s current functioning and secondary conditions. The questions were 
primarily multiple choice style responses, but some write-in responses were included. The 
survey asked caregivers to report if their child’s doctor or healthcare provider ever informed 
them that their child had/has each of 29 conditions. The timing of these conditions included 
any time up to the point of survey completion. Investigators modeled questions about lower 
extremity function after the Vignos Lower Extremity Scale in which the caregiver chooses 
the option that best describes their child’s level of lower extremity physical functioning28. 
Responses about the affected male’s secondary conditions and lower extremity function, and 
caregiver and affected male demographics (e.g. date of birth, date of survey completion) 
were used for this cross-sectional study.
Sample and Methods
Investigators identified eligible caregivers using MD STARnet surveillance data and 
recruited participants from six MD STARnet sites (Arizona, Colorado, Georgia, Hawaii, 
Iowa, and western New York State). Two participants from Hawaii were excluded from 
analyses due to an abbreviated recruitment protocol. Caregivers of living males with definite 
or probable Duchenne or Becker muscular dystrophy were eligible. The sample included 
460 caregivers defined (in priority order) as birth mother, birth father, and legal guardian. 
Only one caregiver was selected per household and, among those with multiple affected 
children, the caregiver was asked to complete the survey for the oldest affected male in the 
household if still living (Figure 1). If the oldest affected male was not living, the caregiver 
was asked to complete the survey for the next oldest sibling. For the majority of caregivers 
(n= 457), the eligible child was the first-born affected male. Caregivers were excluded from 
recruitment if they refused further contact following previous recruitment, were not 
currently the primary caregiver (e.g. individuals who did not have a designated primary 
caregiver or did not live with the caregiver), could not be located during prior recruitment 
efforts, or were identified after recruitment was initiated. Participants completed surveys 
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between April 2011 and February 2012. The protocol and consent for the caregiver survey 
varied by site. Overall, eligible caregivers were invited to complete the survey and could 
refuse participation or opt out at any time. In most sites, consent was implied if the caregiver 
completed and returned the survey, but written consent was required in Colorado. The survey 
was available in English and Spanish and compensation was provided. Each site received 
institutional review board approval for the Family Quality of Life Survey.
Statistical analyses
Two secondary conditions, developmental delay affecting learning and mental retardation/
intellectual disability, were combined into one cognition category called cognitive deficits. 
Ambulation ceased was defined for survey participants using caregiver responses to the 
Vignos scale items and included males who could not walk with assistance, used a 
wheelchair, or were confined to bed28. Additional survey data incorporated in analyses 
included responses about date of survey completion and dates of birth for caregivers and 
affected males.
To evaluate differences between participants and non-participants, the survey data was 
supplemented with surveillance data about sociodemographics, ambulation status, and 
Duchenne or Becker muscular dystrophy phenotype. Sociodemographic information 
included: MD STARnet site, affected male date of birth, race/ethnicity, caregiver relationship 
to the affected male, and neighborhood percent below poverty. Neighborhood percent 
poverty, defined as the percentage of residents in the census tract with household incomes 
below the federal poverty line, was calculated by combining residential information as of the 
most recent clinical visit with U.S. census tract data from The Public Health Disparities 
Geocoding Project Monograph created by the Harvard School of Public Health29. Individual 
race/ethnicity was determined from medical and vital records (non-Hispanic white, 
Hispanic, non-Hispanic Black, Other, Unknown). Age of affected males was grouped into 
four categories (3–10, 11–15, 16–20, 21–31 years of age). Ambulation status (i.e. 
ambulatory versus non-ambulatory) was differentiated by whether an age for ambulation 
cessation was recorded in the surveillance dataset. Affected males were categorized as 
having a Duchenne phenotype if the following criteria were met: 1) ambulation ceased 
before 12 years of age or 16 years of age, when prior to cessation, any steroid use or 
continuous steroid use of at least 24 months was ascertainable, respectively; OR 2) 
observation of an out-of-frame DMD mutation consistent with a Duchenne phenotype or a 
Western blot showing less than or equal to 5% dystrophin; OR 3) onset of symptoms 
occurred before 5 years of age. Affected males were categorized as having a Becker 
phenotype if the following criteria were met: 1) ambulation ceased after 16 years of age, 
regardless of steroid use; OR 2) observation of an in-frame DMD mutation consistent with a 
Becker phenotype or a Western blot showing less than or equal to 20% dystrophin; OR 3) 
onset of symptoms occurred after 10 years of age. Those individuals for whom a Duchenne 
or Becker phenotype could not be determined were assigned an Indeterminate phenotype.
Missing information was limited to at most 4 observations for all variables – with the 
exception of neighborhood percent poverty (52 missing). We excluded individuals with 
missing observations, where appropriate. We included the 52 individuals with missing 
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values for neighborhood percent poverty as ‘unknown’. For analyses describing the 
frequencies of secondary conditions, responses of caregivers about males assigned the 
Indeterminate phenotype were excluded (n=17). We used t-tests to compare mean values for 
continuous variables and chi-square or Fisher exact tests to compare categorical variables. 
We conducted all statistical analyses using SAS version 9.3 (SAS Institute, Cary NC), and 
statistical significance was defined by a p-value < 0.05.
Results
Participants
Of the 460 eligible caregivers, 209 completed the survey, 170 refused, and 81 could not be 
located (Figure 1). Males for whom the surveys were completed were aged 3 to 31 years. 
Using the American Association for Public Opinion Research rate calculator30, we estimated 
an overall response rate of 50.8%, a refusal rate of 28.7%, and a contact rate of 81.0%. 
Using the same calculator, we estimated the cooperation rate for each MD STARnet site: 
75.3% for Arizona, 45.0% for Colorado, 53.8% for Georgia, 81.8% for Iowa, and 82.4% for 
western New York.
Table 1 summarizes differences between participants and non-participants based on 
surveillance data through 2011. Most surveys (95.2%) were completed by biological parents; 
91.4% by females (data not shown). Participants were more likely to be caring for non-
Hispanic white males (71.8%) than non-participants (57.0%). The majority (80.0%) of 
eligible caregivers did not live in a poverty area (i.e. census tracts with poverty rates of 20 
percent or more) (data not shown). For this reason, we stratified eligible participants by the 
median neighborhood percent poverty value (7.5%). Participants were more likely to have a 
known neighborhood percent poverty value and live in a geographical area where less than 
7.5% of its residents had a household income below the federal poverty line than non-
participants. Participant caregivers were more likely to be caring for older males compared 
to non-participants (data not shown). The mean age of males cared for by non-participants 
was 16 years while the mean age of males cared for by participants was 17 years (p=0.04). 
Participation by caregivers was not associated with phenotype or ambulation status of 
affected males.
Descriptive analyses
Of the 209 males whose caregiver completed the survey, there were 164 with the Duchenne 
phenotype, 28 with the Becker phenotype, and 17 with an Indeterminate phenotype. 
Frequencies of secondary conditions in males with Duchenne or Becker phenotypes are 
listed in Table 2. Responses of caregivers of affected males for whom a phenotype could not 
be determined were excluded. In this study, the five most commonly reported secondary 
conditions for males with the Duchenne phenotype were cognitive deficits (38.4%), anxiety 
problems (29.3%), depression (27.4%), constipation (31.7%), and obesity (19.5%) (Table 2). 
Among males with the Becker phenotype, the most frequently reported conditions were 
cognitive deficits (35.7%), depression (28.6%), attention deficit hyperactivity disorder 
(32.1%), constipation (21.4%), and trouble holding urine (21.4%).
Latimer et al. Page 5
J Child Neurol. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Bivariate analyses
Table 3 shows associations between reported secondary conditions and ambulation status of 
affected males with the Duchenne phenotype. Caregivers of ambulatory males were likely to 
report attention deficit hyperactivity disorder compared to those of non-ambulatory males (p 
< 0.01). Conversely, caregivers of non-ambulatory males were more likely to report anxiety 
(p=0.02), depression (p < 0.01), and kidney stones (p=0.02), compared to caregivers of 
ambulatory males. Although not statistically significant, a higher percentage of caregivers of 
non-ambulatory males versus those of ambulatory males reported high blood pressure (p = 
0.07), whereas a higher percentage of caregivers of ambulatory males reported asthma 
compared to caregivers of non-ambulatory males (p = 0.06).
Discussion
In this population-based, cross-sectional study, we described the frequencies of a broad 
range of mental and physical conditions among individuals diagnosed with Duchenne or 
Becker muscular dystrophy and compared frequencies of these conditions by ambulation 
status among males with the Duchenne phenotype. Caregivers of males with Duchenne or 
Becker phenotypes reported secondary conditions affecting cognition, behavior, obesity, 
gastrointestinal, and genitourinary functioning. We did not formally compare differences in 
the frequencies of secondary conditions by phenotype due to small cell counts among those 
with the Becker phenotype. Significant differences in frequencies of selected conditions 
were found by ambulation status for males with the Duchenne phenotype with higher 
frequencies for anxiety, depression, and kidney stones among non-ambulatory males, and a 
higher frequency of attention deficit/hyperactivity disorder among ambulatory males.
Males with Duchenne muscular dystrophy are frequently reported to have an average IQ 
below that of the general population7, 12, 17–20, 31–34. In this study, caregivers were asked to 
report if their child had been diagnosed with cognitive issues that included developmental 
delay affecting learning and mental retardation/intellectual disability. Among those with the 
Duchenne phenotype, 38.4% of caregivers reported at least one of the two cognitive issues. 
When considering the full spectrum of cognitive issues, our estimate falls within the range of 
studies reporting on cognitive function among males with Duchenne muscular 
dystrophy7, 12, 17–20, 31, 32.
Several studies have also focused on behavior problems among males with Duchenne 
muscular dystrophy7, 8, 11–13, 15, 16, 18, 19, 21. In this study, the percentage of caregivers 
reporting attention deficit hyperactivity disorder (14.0%), obsessive compulsive disorder 
(11.0%), or autism spectrum disorder (6.7%) was slightly higher than that reported (11.7%, 
4.8%, and 3.1%, respectively) by caregivers in a larger study by Hendriksen et al. (n=351)21. 
Similar to this study, Caspers Conway et al. found attention deficit hyperactivity disorder in 
18.0% of affected males in MD STARnet using medical record abstraction data (n=765)11. 
In this study, the percentage of males with caregiver-reported depression (27.4%) and 
behavioral/conduct issues (12.2%) differed from those found by Caspers Conway et al., 
which had lower rates of depression (17.0%) , but higher rates of behavior problems 
(26.0%)11. The observed differences are likely a result of data collection methods, attributes 
of the study population including average age, and condition definitions. Of note, the 
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aforementioned behavior problems were more prevalent in this study population than that 
reported for general pediatric and adolescent populations35–40.
Small clinic-based studies have identified co-occurrence of gastrointestinal and nutritional 
issues in the Duchenne population10, 22, 41. It has been suggested that some of these 
problems may be related to reduced gastric motility7, 10. A clinic-based study of 118 patients 
with Duchenne muscular dystrophy by Pane et al. described percentages of their patients 
with weight above 2 standard deviations (3.4%), gastroesophageal reflux needing treatment 
(4.2%), and constipation needing treatment (36.4%)10. In the current report, the 
gastrointestinal and nutritional issues reported most often by caregivers were obesity 
(19.5%), gastroesophageal reflux/heartburn (17.7%), and constipation (31.7%). Jaffe et al. 
reported a similar percentage of heartburn (16.3%) to our study in their 55 patients with 
Duchenne muscular dystrophy22. The frequency of constipation is slightly higher than that 
of the general pediatric population42, 43. However, it is difficult to compare data across 
studies because clinical definitions may vary42–46.
In this study, higher frequencies of anxiety, depression, and kidney stones were found among 
non-ambulatory males when compared to ambulatory males with the Duchenne phenotype. 
The findings of higher frequencies of anxiety and depression among those who are no longer 
able to independently ambulate may be due to increased disease awareness facilitated by 
age-related cognitive development or by emergent symptoms of muscle weakness and 
wasting as disease progresses47. The finding of a higher frequency of kidney stones in non-
ambulatory males with Duchenne muscular dystrophy is consistent with findings from a 
study that used MD STARnet surveillance data as well as other clinic-based studies14, 23–25.
A higher frequency of attention deficit hyperactivity disorder was reported for ambulatory 
males compared to non-ambulatory males with the Duchenne phenotype. These findings 
contradict the statistically non-significant association with ambulation status found by 
Caspers Conway et al., which used MD STARnet surveillance data and statistical methods 
that took into account age at last clinic visit, as well as those of Pane et al. who completed 
formal clinical assessments at the time of determining ambulation status11, 12. Thus, one 
potential confounding factor to the observed difference in this paper may be recall bias due 
to the age of the affected male at survey completion. Attention deficit hyperactivity disorder 
is a childhood disorder and DSM-IV diagnostic criteria requires onset before the age of 7 
years. Less time from diagnosis to survey completion may have contributed to better recall 
of the diagnosis among caregivers of younger, ambulatory children compared to caregivers 
of older, non-ambulatory males.
Limitations of this study include generalizability of study results to the larger patient 
population, which is common of observational studies that rely on subject report. In this 
study, participants were more likely than non-participants to be non-Hispanic White and live 
in census tracts with less than median percent poverty. In addition, the survey was cross-
sectional and did not collect the date when a secondary condition was first diagnosed, which 
prohibited analyses of factors where time ordering was clinically important (e.g., 
corticosteroid use preceding onset of behavior problems) Because of the variability in age of 
the individuals at the time of survey recruitment, caregiver reports may be influenced by 
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recall bias depending on the time elapsed between a secondary condition diagnosis and 
survey participation. Results are also based on caregiver report which could result in under 
or over-reporting of secondary conditions. The small sample size of some conditions 
introduced statistical uncertainty and limited the power of certain conclusions. Finally, this 
study used available clinical data abstracted from medical records to determine Duchenne or 
Becker phenotypes. This resulted in 17 cases being assigned an Indeterminate phenotype 
and exclusion from analyses further reducing our sample size.
Conclusion
According to caregiver reports, males with Duchenne or Becker phenotypes were reported to 
have lifetime diagnoses of conditions affecting cognition, behavior, gastrointestinal, and 
genitourinary functioning. These data support clinical care recommendations for careful 
monitoring of patients with Duchenne or Becker muscular dystrophy by a multidisciplinary 
care team to identify conditions that may be secondary to the diagnosis. Longitudinal 
follow-up of disease progression and the emergence of these conditions would help identify 
potential etiology and aid in their prevention and/or treatment.
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Figure 1. 
Eligibility for the Family Quality of Life Survey
Latimer et al. Page 11
J Child Neurol. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Latimer et al. Page 12
Table 1
Comparison of eligible caregivers who did and did not complete the survey.
Characteristic Participants
N= 209
n (%)
Non-participants
N= 251
n (%)
P value*
Caregiver relationship 0.09
  Biological parent 199 (95.2) 229 (91.2)
  Other 10 (4.8) 22 (8.8)
Neighborhood Percent Poverty† 0.04
  <7.5% 106 (50.7) 102 (40.6)
  ≥7.5% 86 (41.2) 114 (45.4)
  Unknown 17 (8.1) 35 (13.9)
Affected male race/ethnicity <0.01
  Non-Hispanic White 150 (71.8) 143 (57.0)
  Hispanic 30 (14.4) 59 (23.5)
  Non-Hispanic Black 12 (5.7) 17 (6.8)
  Other‡ 4 (1.9) 18 (7.2)
  Unknown 13 (6.2) 14 (5.6)
Phenotype 0.12
  Duchenne 164 (78.5) 212 (84.5)
  Becker 28 (13.4) 29 (11.6)
  Indeterminate 17 (8.1) 10 (4.0)
Age of affected male, years
  3–10 37 (17.7) 58 (23.1) 0.07
  11–15 46 (22.0) 73 (29.1)
  16–20 62 (29.7) 57 (22.7)
  21–31 64 (30.6) 63 (25.1)
Affected male ambulation status 0.47
  Ambulatory 92 (44.0) 119 (47.4)
  Non-Ambulatory 117 (56.0) 132 (52.6)
*χ2 test
†
The percentage of residents in the participant’s census tract whose household income is below the federal poverty level.
‡Asian or Hawaiian or Pacific Islander and Native American or American Indian or Alaska Native
Notes: There is slight variation in denominator values due to the removal of missing responses
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Table 2
Frequencies of caregiver reported secondary conditions in affected males by Duchenne and Becker phenotypes
Secondary Conditions
Duchenne
Muscular
Dystrophy
N=164
n (%)
Becker
Muscular
Dystrophy
N=28
n (%)
Cognitive deficits 63 (38.4) 10 (35.7)
Anxiety problems 48 (29.3) 5 (17.9)
Depression 45 (27.4) 8 (28.6)
Attention deficit disorder/attention deficit hyperactivity disorder 23 (14.0) 9 (32.1)
Behavioral/Conduct problems 20 (12.2) 4 (14.3)
Obsessive-compulsive disorder 18 (11.0) 1 (3.6)
Autism spectrum disorder 11 (6.7) 1 (3.6)
Personality disorder 4 (2.4) 1 (3.6)
Psychiatric disorder 1 (0.6) 0 (0)
Constipation 52 (31.7) 6 (21.4)
Obesity 32 (19.5) 4 (14.3)
Gastroesophageal reflux disease/heartburn 29 (17.7) 3 (10.7)
Failure to thrive/trouble gaining weight 18 (11.0) 0 (0)
Inflammatory bowel disease/Crohn's/ulcerative colitis 4 (2.4) 0 (0)
Gallstones 2 (1.2) 0 (0)
Diabetes 1 (0.6) 0 (0)
Trouble holding urine 21 (12.8) 6 (21.4)
Trouble urinating 15 (9.2) 1 (3.6)
Kidney stones 13 (7.9) 1 (3.6)
High blood pressure 21 (12.8) 1 (3.6)
Asthma 17 (10.4) 2 (7.1)
Cataracts 12 (7.3) 5 (17.9)
Migraines 12 (7.3) 2 (7.1)
Seizures/epilepsy 5 (3.1) 2 (7.1)
Deep vein thrombosis/blood clots in legs 4 (2.4) 0 (0)
Pseudotumor cerebri 3 (1.8) 0 (0)
Cerebral palsy 2 (1.2) 0 (0)
Cancer 1 (0.6) 0 (0)
Notes: Caregivers could report more than one condition; there is slight variation in denominators due to missing responses
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Table 3
Comparisons of secondary conditions among males with Duchenne muscular dystrophy by ambulation status 
(n=164)
Secondary Conditions
Ambulatory*
(N= 45)
n (%)
Non-
ambulatory†
(N= 119)
n (%) p-value‡
Cognitive Deficits 19 (42.2) 44 (37.0) 0.54
Anxiety problems 7 (15.6) 41 (34.5) 0.02
Depression 4 (8.9) 41 (34.5) <0.01
Attention deficit disorder/attention deficit hyperactivity disorder 12 (26.7) 11 (9.2) <0.01
Behavioral/Conduct problems 8 (17.8) 12 (10.1) 0.18
Obsessive-compulsive disorder 3 (6.7) 15 (12.6) 0.40
Autism spectrum disorder 5 (11.1 6 (5.0) 0.18
Constipation 15 (33.3) 37 (31.1) 0.78
Obesity 6 (13.3) 26 (21.9) 0.22
Gastroesophageal reflux disease/heartburn 4 (8.9) 25 (21.0) 0.11
Failure to thrive/trouble gaining weight 4 (8.9) 14 (11.8) 0.78
Trouble holding urine 8 (17.8) 13 (10.9) 0.24
Trouble urinating 1 (2.2) 14 (11.8) 0.07
Kidney stones 0 (0) 13 (10.9) 0.02
High blood pressure 2 (4.4) 19 (16.0) 0.07
Asthma 8 (17.8) 9 (7.6) 0.06
Cataracts 2 (8.4) 10 (8.4) 0.51
Migraines 4 (8.9) 8 (6.7) 0.74
Notes: Participants could report more than one condition across categories; conditions that had ≤5 observations for the total sample are not reported 
here; there is slight variation in denominators due to missing responses
*At a minimum, ability to walk with assistance or long-leg braces
†At a maximum, can stand with long-leg braces, but cannot walk even with assistance
‡χ2 or Fisher’s exact test if the expected cell was <5 observations.
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